Clinical Trial Update: Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating the combination of sorafenib with tegafur/uracil (UFUR) for hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (sorafenib) (sorafenib)
• UFUR (tegafur/uracil)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED